A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

About the trial

Sponsor

Weill Medical College of Cornell University (with Epizyme, Inc., Applebaum Foundation, American Society of Clinical Oncology)

Tested

Tazemetostat Pill (drug)

Dates

Started 2023-10-04; completion 2031-09

Results posted

Not yet

This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.

From ClinicalTrials.gov, last updated 2026-06-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ipsen Biopharmaceuticals, Inc reported $1.7M in research payments for this study in 2025 (6 payments).

Products named: Tazverik, Onivyde

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.